Stockreport

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF Substantial clinical evidence provides rationale to initiate Phase 2 study in PVPhase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 an [Read more]